CA-RAFTR
Silicon Valley-based higher ed tech company Raftr announced today that it will offer its messaging and notifications platform free of charge through July 1, 2020 to colleges and universities, many of which are facing disruption and dislocation as a result of COVID-19 concerns. Each institution’s network is entirely private, limited to that community’s constituents.
The app facilitates immediate and direct communication between college administrations and their students in a mobile-first platform, enabling instant direct messaging to students’ mobile devices.
“Our partner institutions are facing a rapidly evolving COVID-19 outbreak, forcing unprecedented disruption on campuses and in remote learning environments,” Raftr Founder & CEO Sue Decker says. “The right thing to do is to offer our support. Raftr enables immediate communication between universities and their students, faculty, staff, and even parents, anywhere in the world. Exceptionally fast to implement, the interactive, flexible and coordinated communication platform can stand-alone or supplement email communication.”
Raftr enables group administrators to send custom push notifications directly to students’ and parents’ mobile devices, highlighting important updates about issues related to COVID-19, including online learning, study abroad cancellations or updates, academic information, and more.
Key features and customization options for different campus constituents include:
Administration:
- Public and private chat channels for sharing information, and Q&A in real time.
- Optional automatic posting of existing COVID-19 updates from authenticated sources, including CDC, the WHO, and/or existing university sources.
- Curated organization of all past communications for easy discovery and access.
Faculty:
- Ability to host real-time, virtual discussions and “office hours” in private channels for online courses, easily discoverable by students.
- Creation of an online lecture calendar with days / times of courses and ability to link directly to Zoom, Hangouts, or other online learning platforms.
- Direct and group chat options to stay connected to students one-on-one or in class settings.
- Ability to add links to important teaching materials.
Students:
- Creation of digital communities that mirror those on campus, including classes, student groups, social groups, and volunteer organizations.
- Ability to create unlimited public or private groups to maintain student organization communication and planning.
- Access to group chats, topic channels, direct messaging, photos & videos, polls and more.
Decker says the free use of the platform will be granted through July 1. To be eligible, administrators are asked to submit a request to enable their community and attend a one-hour online training session for any staff members who will be posting updates in the platform. Those staff members will be given access to Raftr ProTools, including the ability to send custom push notifications with important updates.
Online Request Form
Submit a request
Connect on Social
Twitter
LinkedIn
Facebook
About Raftr
Raftr promotes the power of belonging by building dynamic and safe digital communities through an intuitive student-centric communication platform. Each enabled school’s experience will be accessible only by that institution’s students, faculty, staff and parents, creating a private, curated, and trusted network. Raftr’s solutions cover every stage of undergraduate and alumni life, with packages for News & Events, Residence Life, Club & Groups / Academic Departments, and Orientation. The platform is available via mobile applications and website, and primary features include events, messaging, push notifications, polls and more. Additional information is available at https://pro.raftr.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200316005649/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom